Luzi Nicole M, Lyons Charles E, Peterson Darrell L, Ellis Keith C
Department of Medicinal Chemistry School of Pharmacy Virginia Commonwealth University Richmond VA USA.
Massey Cancer Center Virginia Commonwealth University Richmond VA USA.
FEBS Open Bio. 2018 Mar 11;8(4):606-613. doi: 10.1002/2211-5463.12396. eCollection 2018 Apr.
Overproduction of cortisol by the hypothalamus-pituitary-adrenal hormone system results in the clinical disorder known as Cushing's syndrome. Genomics studies have identified a key mutation (L205R) in the α-isoform of the catalytic subunit of cAMP-dependent protein kinase (PKACα) in adrenal adenomas of patients with adrenocorticotropic hormone-independent Cushing's syndrome. Here, we conducted kinetics and inhibition studies on the L205R-PKACα mutant. We have found that the L205R mutation affects the kinetics of both Kemptide and ATP as substrates, decreasing the catalytic efficiency (/) for each substrate by 12-fold and 4.5-fold, respectively. We have also determined the IC and for the peptide substrate-competitive inhibitor PKI(5-24) and the ATP-competitive inhibitor H89. The L205R mutation had no effect on the potency of H89, but causes a > 250-fold loss in potency for PKI(5-24). Collectively, these data provide insights for the development of L205R-PKACα inhibitors as potential therapeutics.
下丘脑 - 垂体 - 肾上腺激素系统皮质醇分泌过多会导致一种名为库欣综合征的临床病症。基因组学研究已在促肾上腺皮质激素非依赖性库欣综合征患者的肾上腺腺瘤中,确定了环磷酸腺苷依赖性蛋白激酶(PKACα)催化亚基α - 同工型中的一个关键突变(L205R)。在此,我们对L205R - PKACα突变体进行了动力学和抑制研究。我们发现,L205R突变影响了作为底物的肯普肽(Kemptide)和ATP的动力学,使每种底物的催化效率(/ )分别降低了12倍和4.5倍。我们还测定了肽底物竞争性抑制剂PKI(5 - 24)和ATP竞争性抑制剂H89的IC 和 。L205R突变对H89的效力没有影响,但导致PKI(5 - 24)的效力丧失超过250倍。总体而言,这些数据为开发L205R - PKACα抑制剂作为潜在治疗药物提供了见解。